Seoulin Bioscience Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 14, 2022 at 01:48 am EST
Share
Seoulin Bioscience Co.,Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was KRW 2.08 million compared to KRW 48.42 million a year ago. Net income was KRW 1,172.49 million compared to KRW 13,086.89 million a year ago. Basic earnings per share from continuing operations was KRW 143.4887 compared to KRW 1,560.806 a year ago. Diluted loss per share from continuing operations was KRW 113.2292 compared to diluted earnings per share from continuing operations of KRW 1,560.806 a year ago. Basic earnings per share was KRW 139.5843 compared to KRW 1,560.806 a year ago. Diluted loss per share was KRW 115.1814 compared to diluted earnings per share of KRW 1,560.806 a year ago.
For the nine months, sales was KRW 49.56 million compared to KRW 272.79 million a year ago. Net income was KRW 9,247.67 million compared to KRW 16,226.37 million a year ago. Basic earnings per share from continuing operations was KRW 1,103.9847 compared to KRW 1,929.777 a year ago. Diluted earnings per share from continuing operations was KRW 741.8465 compared to KRW 1,929.777 a year ago. Basic earnings per share was KRW 1,103.9847 compared to KRW 1,933.6815 a year ago. Diluted earnings per share was KRW 741.8465 compared to KRW 1,933.6815 a year ago.
Seoulin Bioscience Co., Ltd is a Korea-based company engaged in the developing and manufacturing of basic equipment for bio research. The Company mainly engages in research and development of reagents, such as deoxyribonucleic acid (DNA) chips, which are used for gene therapy, clinical diagnosis, organs transplantation and biopsy; stem cells, which are used for treatment of incurable diseases, Alzheimer disease and others, and next-generation biotechnology drugs. The company supplies its products under the brand name MyLab. It also imports bio research equipment from Thermo Fisher, Affymetrix, Sarstedt and others, and markets in the domestic market. In addition, the Company engages in the real estate rental business.
SEOULIN BIOSCIENCE CO.,LTD. 
